Weight Loss Peptides
Tirzepatide
Tirzepatide was developed to fight type 2 diabetes, but has additionally been shown to protect the cardiovascular system. Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality as well. This combination allows Tirzepatide to lower blood glucose levels, increase insulin sensitivity, boost feelings of satiety.
Semaglutide
Semaglutide is a derivative of the naturally occurring GLP-1, a peptide that has been shown to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease. Research with Semaglutide has shown it can significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Glucagon-Like Peptide-1 (GLP-1) Analogs have been shown to stimulate insulin and suppress glucagon secretion in a glucose-dependent manner.
Retatrutide
Retatrutide is a GGG tri-agonist that targets GLP-1 and GIP receptors, akin to standard GLP-1 agonists, but also uniquely activates the glucagon receptor. This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists. Further research is required.
Cagrilintide
Cagrilintide is a long-acting analogue of amylin, a naturally occurring peptide that is released in conjunction with insulin. Cagrilintide has shown promise in animal trials as a treatment for obesity and type 2 diabetes. It has been studied for benefits not just in type 2 diabetes, but for liver damage, alcohol-related liver disease, and heart/blood vessel disease. There is some speculation about the role of this peptide in Alzheimer’s disease as well, but no research has been published in that particular sub-domain, yet. Many trials, however, have looked at the combination of cagrilintide and semaglutide in the treatment of obesity and type 2 diabetes. The two proteins appear to work synergistically to provide more robust and more permanent weight loss effects. It is important to note that while preclinical studies suggest promising therapeutic potential, clinical trials in humans are limited. Further research needs to be done to determine the efficacy and safety profiles.
GHRP-2 Acetate
GHRP-2 is a synthetic growth hormone secretagogue that binds to the ghrelin/growth hormone secretagogue receptor. It has been shown in research trials to improve muscle growth, regulate the immune system, and improve sleep cycles. GHRP-2 research has shown that it has oral bio-activity.
GHRP-6 Acetate
GHRP-6 is a synthetic ghrelin/growth hormone secretagogue agonist. It has positive effects on appetite, heart muscle cells, scar formation, and sexual motivation. Animal studies show this orally active growth hormone secretagogue also improves memory function and may help to thwart the neurological effects of Parkinson’s disease.
Sermorelin Acetate
Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue that has been used to assess and stimulate natural growth hormone secretion. It is of interest to researchers for its ability to improve bone density, reduce scaring, fight the effects of dementia, and reduce seizure activity.
AOD9604
AOD9604 is a modified version of the hGH fragment 176-191 peptide (contains a di-sulfide bridge) and thus a derivative of human growth hormone (hGH). Originally developed as a lipolytic (fat burning) compound, AOD9604 has shown benefit in studies of heart disease, osteoarthritis/cartilage repair, and metabolic syndrome. AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis in animal studies.
Tesamorelin
Tesamorelin, is a syntheitic peptide consiting of 44 amino acids. It is a growth-hormone-releasing hormone (GHRH) analogue researched for the treatment of HIV-associated lipodystrophy (dysfunctional, toxic fat deposition). It is also being researched for its ability to improve peripheral nerve health, slow the progression of mild cognitive impairment, and the reduction visceral fat. This peptide has been found to reduce adiposity by nearly 20% in this population [1]. Research suggests that tesamorelin is approximately 4 times more effective in reducing adiposity than all of the other available therapies combined.
Ipamorelin
Ipamorelin is a short peptide sequence capable of binding to the ghrelin/growth hormone secretagogue receptor. It is one of the most selective growth hormone (GH) secretagogues known and has been shown in laboratory studies to have no effect on ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, or cortisol release [1]. Given its high level of specificity, ipamorelin has been of interest in research both as a therapeutic in and of itself as well as a model peptide for understanding how selectivity in GH receptor binding is achieved. Its presence plays a key role in the overall growth and repair of musculoskeletal tissue.
KissPeptin-10
Kisspeptin acts to control hormone secretion as it relates to reproduction. Kisspeptin has been shown to influence testosterone levels and sex-related behaviors like drive and motivation. Research also suggests it may help to reverse some of the effects of aging.
KPV
KPV is a potent anti-inflammatory peptide that has shown promise in a number of disease conditions. The most active research is in the treatment of inflammatory bowel disease where the peptide has showed substantial promise. Research in wound healing also reveals that KPV and other alpha-MSH derivatives may offer a host of benefits that speed wound healing, reduce infection, fight inflammation, and lead to better cosmetic results. KPV and similar peptides could become mainstays not just in wound healing, but in scar reduction following surgery.
MOTS-c
MOTS-c is a small protein made in the mitochondria, often referred to as the cell's powerhouse, and it helps regulate how our cells use energy. By affecting how the body processes glucose and responds to insulin, MOTS-c plays a role in maintaining a healthy balance in metabolism. It works by moving to the cell’s nucleus, where it influences certain genes related to energy production and stress response, especially when the body is under metabolic stress. Research suggests MOTS-c may help support better glucose control and could be useful in addressing metabolic issues and age-related health concerns. MOTS-c has been shown to promote metabolic homeostasis and longevity, & improve exercise capacity, reduce obesity, insulin resistance and other disease processes such as osteoporosis.
the immune system, and improve sleep cycles. GHRP-2 research has shown that it has oral bio-activity.
HGH(HG)
HGH Fragment 176-191 is a small, synthetic piece of natural human growth hormone (hGH). It is often referred to as the “lipolytic fragment” for its ability to boost fat loss. It has been shown to help lower blood sugar levels and promote cartilage healing without increasing long bone growth, increasing IGF-1 levels, or altering insulin sensitivity.
5-amino-1mq
5-amino-1MQ is a small molecule that blocks the activity of the enzyme called nicotinamide N-methyltransferase (NNMT). NNMT is a very important component in metabolism and energy and is predominantly active in fat tissue. By blocking NNMT, 5-amino-1MQ stimulates an increase in nicotinamide adenine dinucleotide (NAD+), a cofactor that is central to cellular metabolism, thereby increasing metabolic rate and activating a gene called sirtuin-1 (SIRT1).
SIRT1 is also known as the "longevity gene" because of its role in reducing the risk of diabetes, obesity, metabolic syndrome, atherosclerosis and other forms of cardiovascular disease, kidney disease, liver disease, neurodegeneration, and cancer. Research in mice given 5-amino-1MQ showed a 7% reduction in body mass over 10 days without any changes in food intake, compared to controls. Research has shown that decreasing NNMT may help shrink fat cells and reduce the size of fat deposits.